Live Breaking News & Updates on Seth Wander

Stay updated with breaking news from Seth wander. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024

COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) ....

Dana Farber Cancer Institute , United States , Dsenthil Damodaran , Simon Jenkins , Paul Plourde , Elizabeth Attias , David Portman , Barry Komm , Miriam Portman , Harvard Medical School , Parke Davis Pharmaceuticals , University Of Miami , Sermonix Pharmaceuticals Inc , Phd Md Anderson Cancer Center , Hospital Cancer Center , Phd Harvard Medical School , Cornell University , American Society Of Clinical Oncology , Md Anderson Cancer Center , Pharmaceuticals Inc , Cancer Center , Seth Wander , Massachusetts General Hospital , Evaluating Lasofoxifene , Investigational Cancer Therapeutics , American Society ,

Dr Wander on Genomic Alterations in ER+/HER2– Metastatic Breast Cancer

Seth Wander, MD, PhD, discusses findings from an analysis of baseline genomic alterations in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who were enrolled in the single-arm, phase 2 ELAINE-2 trial of lasofoxifene plus abemaciclib. ....

United States , Harvard Medical School , Seth Wander , Massachusetts General Hospital , Patients With Estrogen Receptor Positive , Er2 Negative Metastatic Breast Cancer , Elaine 2 Trial , Lasofoxifene Plus Abemaciclib ,

Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer

Durable responses with lasofoxifene plus abemaciclib in post-CDK4/6 inhibitor setting ....

United States , Mayo Clinic In Rochester , Matthew Goetz , Dsenthil Damodaran , Charles Bankhead , University Of Texas Md Anderson Cancer Center , Harvard Medical School , Cancer Center , Mayo Clinic , Seth Wander , Massachusetts General Hospital , Medpage Today ,

Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy

/PRNewswire/ Regor Therapeutics Group ("Regor"), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development. ....

United States , San Antonio , Prnewswire Regor Therapeutics Group , Regor Therapeutics Group , First In Human Phase , Therapeutics Group , Seth Wander , Massachusetts General Hospital , San Antonio Breast Cancer Symposium , Chief Executive Officer , Regor Therapeutics , Computer Accelerated Rational Discovery ,

Expert Insights on the United States Chemotherapy Shortage

Oncology experts discuss the platinum chemotherapy shortage in the United States. ....

Mayo Clinic In Rochester , United States , Dana Farber Cancer Institute , New Haven , Yale School , Danielp Petrylak , Paolo Tarantino , Edgardo Santos , Lionela Kankeu Fonkoua , Solange Peters , Ashling Wahner , National Comprehensive Cancer Network , Genitourinary Oncology At Yale Cancer Center , Thoracic Malignancies Programme , University Hospital Of Lausanne , Harvard Medical School , Practices Committee , Florida Society Of Clinical Oncology , European Institute Of Oncology , Yale School Of Medicine , Department Of Oncology , Best Practices Committee , Massachusetts General Hospital , European Institute , Genitourinary Oncology , Yale Cancer Center ,